Anne Li March 11th, 2018
Three thyroid cancer treatments have been approved for routine use on the NHS in England. The recommendation by the National Institute for Health and Care Excellence (NICE) will move cabozantinib (Cometriq) and sorafenib (Nexavar) from the Cancer Drugs Fund. Lenvatinib (Lenvima) was the third drug to be approved, after previously being available only on compassionate grounds.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2018-02-23-three-thyroid-cancer-drugs-approved-for-nhs-in-england